CIA
ALNY icon

Concurrent Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Concurrent Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
7,521
+6,576
+696% +$1.98M 0.02% 680
2026
Q1 		$313K Buy
945
+143
+18% +$48.7K ﹤0.01% 1475
2025
Q4 		$319K Buy
+802
New +$355K ﹤0.01% 1355

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concurrent Investment Advisors's ALNY Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 696% in Q2 2026, buying an estimated $1.98M and bringing the position to 7,521 shares worth $2.26M. The position accounts for 0.02% of the portfolio, ranked #680.

Concurrent Investment Advisors first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Concurrent Investment Advisors held 7,521 shares of Alnylam Pharmaceuticals worth $2.26M as of Q2 2026.
  • Concurrent Investment Advisors bought 6,576 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.98M.
  • Alnylam Pharmaceuticals made up 0.02% of Concurrent Investment Advisors's portfolio in Q2 2026, its #680 holding.
  • Concurrent Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.